Agree, tricky time, I do not want to hear the same talk again...

Agree, tricky time, I do not want to hear the same talk again rehashed.....I have already heard it multiple time before, and I think that giving the same spiel over and over actually detracts from investor confidence and lacks credibility, therefore why would we do it if we did not have to. It's now time for the rubber to hit the road in terms of data sets (positive of course!), license agreements etc. I assume (and hope) that behind the scenes there is a lot of work going on related to this aspect, otherwise there is nothing to shore up the SP and who knows where the "floor" of this SP is set to head to, as stated previously, small cap biotechs live and die by partnerships, licensing agreements and positive data sets that are able to disrupt incumbents, GLTAH, stay well